Royalty Pharma (RPRX) FY2025 10-K Risk Factors: 5 New, 12 Dropped

What the changes say

Royalty Pharma completed its internal management transition, taking on direct overhead, employee liabilities, and subsidiary dependence risks.
Litigation risks emerged regarding Vertex underpaying Alyftrek royalties.
Top five product franchises generated 61% of royalty receipts.

What changed since the prior 10-K

New

NewRisks Relating to Our Business
The success of our business depends on key members of our team
We rely heavily on key professionals to source biopharmaceutical asset acquisitions through their industry relationships.
NewRisks Relating to Our Business
Unsuccessful attempts to acquire new royalties could result in significant costs, divert management attention and adversely affect our ability to pursue other investment opportunities
Unsuccessful royalty acquisition attempts can cause unrecoverable advisory costs and divert management attention from other investments.
NewRisks Relating to Our Organization and Structure
We are a holding company and rely on cash generated by our subsidiaries to meet our financial obligations
As a holding company, we depend on subsidiary cash flow and face restrictions that could limit our ability to pay dividends.
NewRisks Relating to Our Organization and Structure
We may not realize the anticipated benefits of the Internalization or we may be exposed to new risks and costs
Following our Internalization on May 16, 2025, our direct overhead and exposure to employer-related liabilities have increased.
NewRisks Relating to Our Ordinary Shares
These and other factors may cause significant fluctuations in the market price or trading volume of our Class A ordinary shares, which may limit our shareholders’ ability to sell their Class A ordinary shares at prices they consider satisfactory or at all
Our Articles of Association designate exclusive forums for shareholder complaints, limiting where lawsuits can be filed.

Dropped

DroppedRisks Relating to Our Business
We do not employ our own personnel and are entirely dependent upon the Manager for all the services we require
DroppedRisks Relating to Our Business
The success of our business depends upon key members of the Manager’s advisory team who may not continue to work for the Manager
DroppedRisks Relating to Our Business
Unsuccessful attempts to acquire new royalties could result in significant costs and negatively impact subsequent attempts to locate and acquire other assets
DroppedRisks Relating to Our Organization and Structure
We are a holding company with no operations and rely on our subsidiaries to provide us with the funds necessary to meet our financial obligations and to pay dividends
DroppedRisks Relating to Our Organization and Structure
The Manager may be the subject of a change of control resulting in a disruption in our operations that could adversely affect our business, financial condition or results of operations
DroppedRisks Relating to Our Organization and Structure
The Manager’s liability is limited under the Management Agreement, and we have agreed to indemnify the Manager against certain liabilities. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable
Reliance on external Manager
DroppedRisks Relating to Our Internalization
The Internalization may not close due to a variety of factors, including the failure or significant delay in obtaining required regulatory approvals, and, even if it does close, we may not realize the anticipated benefits
Reliance on Manager's advisory team
DroppedRisks Relating to Our Internalization
The Share Consideration in connection with the Internalization, and future sales of our Class A ordinary shares by the Sellers may adversely affect the market price of our Class A ordinary shares
DroppedRisks Relating to Our Internalization
Certain of our officers and directors have interests in the Internalization that are different from, and may potentially conflict with, the interests of us and our shareholders
DroppedRisks Relating to Our Internalization
We may be exposed to risks to which we have not historically been exposed, including liabilities with respect to the assets acquired from the Manager
DroppedRisks Relating to Our Ordinary Shares
These and other factors may cause the market price of and demand for our Class A ordinary shares to fluctuate significantly, which may limit or prevent our shareholders from reselling their Class A ordinary shares at or above the purchase price
DroppedRisks Relating to Our Ordinary Shares
The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members

Reworded

84% rewrittenRisks Relating to Taxation
Legal claims and proceedings could adversely affect our business
Added disclosure that Vertex did not pay the full amount of Alyftrek royalty receipts starting in the second quarter of 2025.
71% rewrittenRisks Relating to Our Business
Biopharmaceutical products are subject to sales risks
Added approval delays, prescribing declines, and reimbursement rate drops as factors lowering biopharmaceutical product sales.
65% rewrittenRisks Relating to Our Business
There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective
Updated conflict of interest disclosures to name CEO Mr. Legorreta's role and investment in Pharmakon Advisors and BioPharma Credit.
Was: There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective in doing so
59% rewrittenRisks Relating to Taxation
Corporate responsibility matters and any related reporting obligations may impact our business
Expanded corporate responsibility risks to include multiple overlapping reporting standards and enhanced regulatory enforcement exposure.
55% rewrittenRisks Relating to Our Business
Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation
Updated top five product franchises' share of Royalty Receipts to 61% in 2025 and added internal rate of return impacts.
52% rewrittenRisks Relating to Our Ordinary Shares
The market price of our Class A ordinary shares has been and may in the future be volatile, which could cause the value of our shareholders’ investment to decline
Updated share price trading range to a low of $25.75 and a high of $40.78 for 2025.
49% rewrittenRisks Relating to Taxation
Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis
Retained complex international tax law and OECD review risks without material textual changes.
47% rewrittenRisks Relating to Our Business
Our business is subject to interest rate, foreign exchange, inflation and banking industry risk
Added Term Loan borrowings and Portfolio Cash Flow impacts to interest rate risk disclosures.
46% rewrittenRisks Relating to Our Organization and Structure
Our structure will result in tax distributions as a result of the RP Holdings Class C Special Interest
42% rewrittenRisks Relating to Our Business
We face competition in acquiring royalties and locating suitable royalties to acquire
32% rewrittenRisks Relating to Our Organization and Structure
Equity Performance Awards may create incentives that are not fully aligned with the interests of our shareholders
Was: The equity performance awards payable to an affiliate of the Manager may create incentives that are not fully aligned with the interests of our shareholders
31% rewrittenRisks Relating to Our Business
We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties we acquire do not generate sufficient income
Was: We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us
29% rewrittenRisks Relating to Our Business
The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business
25% rewrittenRisks Relating to Taxation
We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case
24% rewrittenRisks Relating to Our Business
Information available to us about the biopharmaceutical products underlying the royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited
23% rewrittenRisks Relating to Our Business
We may undertake strategic acquisitions of operating biopharmaceutical companies or acquire securities of biopharmaceutical companies. Our failure to realize the expected benefits of such acquisitions could adversely affect our business, financial condition or results of operations
Was: We may undertake strategic acquisitions of operating biopharmaceutical companies or acquire securities of biopharmaceutical companies. Our failure to realize expected benefits of such acquisitions could adversely affect our business, financial condition or results of operations
21% rewrittenRisks Relating to Our Business
The products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations, pricing pressures and the regulation of the healthcare industry

All 52 risk factors

Headings as the filing states them, in filing order.

Risks Relating to Our Business

01Biopharmaceutical products are subject to sales risks71% rewritten
02The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business29% rewritten
03Acquisitions of royalties from our investments in development-stage biopharmaceutical product candidates are subject to additional risks and uncertainties
04We may undertake strategic acquisitions of operating biopharmaceutical companies or acquire securities of biopharmaceutical companies. Our failure to realize the expected benefits of such acquisitions could adversely affect our business, financial condition or results of operations23% rewritten
05We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties we acquire do not generate sufficient income31% rewritten
06The success of our business depends on key members of our teamNew
07There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective65% rewritten
08Our business is subject to interest rate, foreign exchange, inflation and banking industry risk47% rewritten
09Information available to us about the biopharmaceutical products underlying the royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited24% rewritten
10Our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns
11We make assumptions regarding the royalty duration for terms that are not contractually fixed, and a shortened royalty term could result in a reduction in the effective interest rate, a decline in income from royalties, significant reductions in royalty payments compared to expectations, or a permanent impairment
12Most of our royalties are classified as financial assets that are measured at amortized cost using the effective interest method as a result of which our GAAP results of operations can be volatile and unpredictable
13Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation55% rewritten
14We face competition in acquiring royalties and locating suitable royalties to acquire42% rewritten
15Biopharmaceutical products are subject to substantial competition
16Marketers of products that generate our royalties are outside of our control
17The marketers of biopharmaceutical products are, generally, entirely responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products
18License agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our royalties
19The insolvency of a marketer could adversely affect our receipt of cash flows on the related royalties that we hold
20Unsuccessful attempts to acquire new royalties could result in significant costs, divert management attention and adversely affect our ability to pursue other investment opportunitiesNew
21The products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations, pricing pressures and the regulation of the healthcare industry21% rewritten
22The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold
23Sales of products that generate our royalties are subject to regulatory approvals and actions in the United States and foreign jurisdictions that could harm our business
24The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies
25Product liability claims may diminish the returns on biopharmaceutical products
26We are typically not involved in maintaining, enforcing and defending patent rights on products that generate our royalties
27The existence of third-party patents in relation to products may result in additional costs for the marketer and reduce the amount of royalties paid to us
28Disclosure of trade secrets of marketers of products could negatively affect the competitive position of the products underlying our biopharmaceutical assets
29Our board of directors may make decisions with respect to the cash generated from our operations that may result in our not paying dividends or not repurchasing our ordinary shares
30The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio

Risks Relating to Our Organization and Structure

31We are a holding company and rely on cash generated by our subsidiaries to meet our financial obligationsNew
32Our structure will result in tax distributions as a result of the RP Holdings Class C Special Interest46% rewritten
33Our ability to pay periodic dividends to our shareholders or make share repurchases may be limited by applicable provisions of English law and contractual restrictions and obligations
34If we were determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could adversely affect our business, financial condition or results of operations
35Equity Performance Awards may create incentives that are not fully aligned with the interests of our shareholders32% rewritten
36Operational risks may disrupt our businesses, result in losses or limit our growth
37The EU directive on alternative investment fund managers (the “AIFM Directive”) may significantly increase our compliance costs
38We may not realize the anticipated benefits of the Internalization or we may be exposed to new risks and costsNew

Risks Relating to Our Ordinary Shares

39The market price of our Class A ordinary shares has been and may in the future be volatile, which could cause the value of our shareholders’ investment to decline52% rewritten
40These and other factors may cause significant fluctuations in the market price or trading volume of our Class A ordinary shares, which may limit our shareholders’ ability to sell their Class A ordinary shares at prices they consider satisfactory or at allNew
41U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management
42The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation
43As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure
44If our Class A ordinary shares are not eligible for continued deposit and clearing within the facilities of DTC, then transactions in our securities may be disrupted

Risks Relating to Taxation

45Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis49% rewritten
46We could be liable for significant taxes due to changes in our eligibility for certain income tax treaty benefits or challenges to our tax positions with respect to the application of income tax treaties
47We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case25% rewritten
48Cybersecurity vulnerabilities, failures in information systems or risks associated with the use of artificial intelligence could result in information theft, data corruption and significant disruption of our business operations
49Changes in the application of accounting standards issued by the U.S. Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements
50The outbreak of infectious or contagious diseases could adversely affect our results of operations, financial condition and cash flows
51Legal claims and proceedings could adversely affect our business84% rewritten
52Corporate responsibility matters and any related reporting obligations may impact our business59% rewritten

Other Royalty Pharma 10-Ks

FY2024 10-K risk factors
59 risks
Royalty Pharma faces high dependence on its external manager for sourcing biopharmaceutical royalties and key executives like Mr. Legorreta. High leverage and concentrated product revenue of 64% from top five franchises drive business risk. Financial results are exposed to volatile amortized cost accounting for royalty assets and intense market competition.
Filed Feb 12, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.